Summit Global Investments reduced its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 22.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,310 shares of the company’s stock after selling 6,927 shares during the quarter. Summit Global Investments’ […]